Harmony Biosciences Holdings, Inc. (HRMY)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Rare Neurological Diseases	868.45M	714.73M	582.02M	437.86M	305.44M
Rare Neurological Diseases Growth	21.51%	22.80%	32.93%	43.35%	91.21%
Total	868.45M	714.73M	582.02M	437.86M	305.44M
Total Growth	21.51%	22.80%	32.93%	43.35%	91.21%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
United States (U.S.)	868.45M	714.73M	582.02M	437.86M	305.44M
United States (U.S.) Growth	21.51%	22.80%	32.93%	43.35%	91.21%
Total	868.45M	714.73M	582.02M	437.86M	305.44M
Total Growth	21.51%	22.80%	32.93%	43.35%	91.21%

Data Source: S&P Global Market Intelligence Last updated: May 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 26, 2026

Data Sources Report a data error